Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To …
3 days ago · On Monday, the European Commission approved GSK plc’s (NYSE:GSK) Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients ...
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
Next stage in GSK’s Zantac defense gets underway today
1 day ago · GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The pharma sales...
GSK enters agreement to acquire IDRx, Inc. | GSK
Jan 13, 2025 · Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers GSK to pay up to $1.15 billion GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision ...
GSK to Buy US Biotech Firm IDRx for up to $1.15 Billion - U.S. News
Jan 13, 2025 · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based ...
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits ...
Oct 9, 2024 · GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.
Press releases | GSK US
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD. GSK announced results of MATINEE, evaluating Nucala, a monoclonal antibody that targets interleukin-5 (IL-5) in adults with COPD. Download (PDF, 429.6KB)
GSK makes a strong start to 2024 with improving outlook for the …
May 1, 2024 · "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines.
GSK plc (GSK) Latest Press Releases & Corporate News - Yahoo …
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
GSK, Merck and Pfizer in Ab&B's sights as biotech files for IPO
1 day ago · Currently, GSK’s Shingrix is the only recombinant vaccine against herpes zoster, also known as shingles, approved for use in China. However, Ab&B’s chances of launching the second recombinant ...